Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 6/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 5/20 | 0.33 |
| ▸ | HTR2C | P28335 | 3/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL292398 | 0.72 | CYP1A2 (0.40) | — | |
| SCHEMBL9652405 | 0.69 | HTT (0.45) | — | |
| SCHEMBL2253481 | 0.69 | HPRT1 (0.35) | — | |
| SCHEMBL1715574 | 0.68 | HTR2C (0.33) | PDK2PDK4HTR2CADRB2 | |
| SCHEMBL1716898 | 0.67 | HIPK2 (0.31) | — | |
| SCHEMBL10081901 | 0.66 | HTR2C (0.38) | PDK2PDK4HTR2C | |
| SCHEMBL699268 | 0.63 | KDM4E (0.30) | — | |
| SCHEMBL7088652 | 0.63 | MAPT (0.47) | — | |
| SCHEMBL10085450 | 0.63 | CYP1A2 (0.56) | PDK2PDK4HTR2CPDK1 | |
| SCHEMBL30449404 | 0.63 | CYP1A2 (0.56) | PDK2PDK4HTR2CPDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324223-B2 | Substituted thieno [2,3-d] pyrimidines as HIV inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120225894-A1 | Substituted Thienol[2,3-d] pyrimidines as HIV Inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-8211898-B2 | Substituted thieno[3,2-d]pyrimidines as HIV inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2132211-A2 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | Ardea Biosciences, Inc. (US) | 2009-12-16 | — | — | EP | disclosed |
| US-20090281124-A1 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | ARDEA BIOSCIENCES (US) | 2009-11-12 | — | — | US | disclosed |
| US-7595324-B2 | Substituted thieno[3,2-D]pyrimidines as HIV inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080176871-A1 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| WO-2008058285-A2 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176871-A1 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | CYCS, DCK, NSUN2 | PDK2 1860/4885PDK4 1507/4885HTR2C 3218/4885 |
| US-20120225894-A1 | Substituted Thienol[2,3-d] pyrimidines as HIV Inhibitors | TYMS, DUT, TYMP | PDK2 1292/4885PDK4 2053/4885HTR2C 2529/4885 |
| US-20090281124-A1 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | CYCS, DCK, NSUN2 | PDK2 1860/4885PDK4 1507/4885HTR2C 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.